Member Directory

chemotherapy resistance and metastasis. Through our groundbreaking research and development of ALDH1A3-targeted therapies, we aim to deliver life-changing solutions for patients worldwide. Founded by leading scientists from Dalhousie University in Nova Scotia, Canada, and the University of Pisa, Italy, Theranib combines world-class expertise in molecular cancer biology and medicinal chemistry. Our proprietary compound, represents a first-in-class therapeutic innovation designed to enhance the effectiveness of cancer treatments and improve patient outcomes.

the globe. We come up with new approaches to addressing today’s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We’re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself. At AbbVie, we see a future full of possibility, where health is in reach and patient lives are improved.

are transforming the future of healthcare by unlocking the power of what science can do, for people, society and the planet. Leading in Canadian Health Sciences and R&D AstraZeneca has the largest research and development (R&D) footprint in the Canadian health sciences sector, based on the number of employees and number of Canadian clinical trials. We employ more than 2,100 people in Canada dedicated to researching, developing and marketing innovative medicines. Recently designated as a global Clinical R&D hub, AstraZeneca Canada is leading global clinical studies in oncology, biopharmaceuticals and rare disease. The future of treatment for many of today’s diseases lies in uncovering mechanisms that are newly emerging or are still to be discovered. We believe the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them.

on areas of significant unmet medical need. At Novartis Canada, we are committed to working with all stakeholders within the health care ecosystem to ensure that every Canadian has equitable access to the innovative medicines they need. We are determined to be a valued partner and advocate, with a deep understanding of patient needs along the entire care journey – from drug development, to diagnosis, to access and beyond. Part of the way we are doing this is by leveraging data, technology, and partnerships. We foster a work environment and culture that brings out the best in people to fulfil our purpose of reimagining medicine to improve and extend people’s lives. We operate with the understanding that associates are our greatest asset and encourage them to live the values and behaviors that underpin this culture.

chemotherapy resistance and metastasis. Through our groundbreaking research and development of ALDH1A3-targeted therapies, we aim to deliver life-changing solutions for patients worldwide. Founded by leading scientists from Dalhousie University in Nova Scotia, Canada, and the University of Pisa, Italy, Theranib combines world-class expertise in molecular cancer biology and medicinal chemistry. Our proprietary compound, represents a first-in-class therapeutic innovation designed to enhance the effectiveness of cancer treatments and improve patient outcomes.

the globe. We come up with new approaches to addressing today’s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We’re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself. At AbbVie, we see a future full of possibility, where health is in reach and patient lives are improved.

are transforming the future of healthcare by unlocking the power of what science can do, for people, society and the planet. Leading in Canadian Health Sciences and R&D AstraZeneca has the largest research and development (R&D) footprint in the Canadian health sciences sector, based on the number of employees and number of Canadian clinical trials. We employ more than 2,100 people in Canada dedicated to researching, developing and marketing innovative medicines. Recently designated as a global Clinical R&D hub, AstraZeneca Canada is leading global clinical studies in oncology, biopharmaceuticals and rare disease. The future of treatment for many of today’s diseases lies in uncovering mechanisms that are newly emerging or are still to be discovered. We believe the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them.

on areas of significant unmet medical need. At Novartis Canada, we are committed to working with all stakeholders within the health care ecosystem to ensure that every Canadian has equitable access to the innovative medicines they need. We are determined to be a valued partner and advocate, with a deep understanding of patient needs along the entire care journey – from drug development, to diagnosis, to access and beyond. Part of the way we are doing this is by leveraging data, technology, and partnerships. We foster a work environment and culture that brings out the best in people to fulfil our purpose of reimagining medicine to improve and extend people’s lives. We operate with the understanding that associates are our greatest asset and encourage them to live the values and behaviors that underpin this culture.